GBD2013 Tuberculosis estimates of mortality, incidence and prevalence

Similar documents
The global burden of tuberculosis: results from the Global Burden of Disease Study 2015

TB Disease Prevalence Survey - Progress Report

TB, BCG and other things. Chris Conlon Infectious Diseases Oxford

Global TB control: Current status with particular attention to TB among women and children

WHO Global Task Force on TB Impact Measurement An overview

Latest developments in WHO estimates of TB disease burden

Appendix 3 Sample size and cost of surveys

Estimates of TB incidence, prevalence and mortality. Philippe Glaziou Cairo, October 2009

Mathematical modelling approach to estimating TB burden in children Pete Dodd (University of Sheffield) & James Seddon (Imperial College London)

TB Disease Prevalence Survey - Overview, why and how

Supplementary appendix

Estimating TB burden. Philippe Glaziou World Health Organization Accra, Ghana

WHAT'S IN A NUMBER? TWO RECENT REPORTS ESTIMATING CHILDHOOD TB CASES.

Annex 2 A. Regional profile: West Africa

TB Disease Prevalence Survey - Overview and Introduction of the TF

Global malaria mortality between 1980 and 2010: a systematic analysis

The epidemiology of tuberculosis

Predictive statistical modelling approach to estimating TB burden. Sandra Alba, Ente Rood, Masja Straetemans and Mirjam Bakker

National TB prevalence surveys

Global Burden of Disease Study - Tuberculosis

TB and Diabetes Intersection of Two Diseases

Helping TB patients quit smoking: the potential impact, WHO recommendations and country experience

Investing for Impact

Measuring progress in global tuberculosis control: WHO Policy and Recommendations DRAFT

Systematic analysis of national, regional, and global trends in. chronic kidney disease mortality, morbidity, and etiology. Sarah Wulf.

Estimating the global burden of tuberculosis. WHO estimates of TB incidence, prevalence and mortality, by country,

The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America

Tackling the epidemic of chronic noncommunicable disease in sub Saharan Africa: established priorities and new concerns

Disclosures. TB and CoMorbidities Challenges and Opportunities. Burden of TB. Outline of the lecture. Target testing for TB Infection TB HIV 3/25/2012

REVIEW OF TUBERCULOSIS EPIDEMIOLOGY

BACKGROUND DOCUMENT 4e. Prevalence surveys of TB disease post-2015 Why, How, Where?

Current State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2

Eligibility List 2018

Recipients of development assistance for health

HIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR

Global TB Report 2015: Technical appendix on methods used to estimate the global burden of disease caused by TB

WHO Task Force Framework on assessment of TB surveillance data - Revisiting the "Onion model" Ana Bierrenbach WHO consultant Nov/Dec 2010

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific

Malaria Burden Estimation Evidence Review Group (MBE-ERG)

The Burden of Heart Failure in the Asia Pacific. Eugenio B. Reyes, M.D. Associate Professor, University of the Philippines, College of Medicine

Global, National, Regional

The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific

Global, National, Regional

What we need to know: The role of HIV surveillance in ending the AIDS epidemic as a public health threat

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB

BCG. and your baby. Immunisation. Protecting babies against TB. the safest way to protect your child

Articles. Funding Bill & Melinda Gates Foundation. GBD 2013 Mortality and Causes of Death Collaborators*

EPIDEMIOLOGY OF TUBERCULOSIS AND the IMPACT ON CHILDREN

Please evaluate this material by clicking here:

GLOBAL TB IMPACT MEASUREMENT

Strengthening Lab Capacity for TB Diagnosis and Care in LMICs

What is this document and who is it for?

Epidemiology and economics: modelling the scenarios for the end of AIDS

#4 (Tuberculosis OR TB OR Pulmonary Tuberculosis OR Multi-Drug Resistant Tuberculosis OR MDR OR Extremely-Drug Resistant Tuberculosis or XDR)

Humanitarian Initiative to Prepare for a Pandemic Influenza Emergency (HIPPIE) Ron Waldman, MD Avian and Pandemic Influenza Unit USAID/Washington

GLOBAL TUBERCULOSIS REPORT EXECUTIVE SUMMARY

Asia s Diabetes Challenge

Supplementary appendix

Rehabilitation in Hospital Authority- Challenges and the Way Ahead

Impact Dashboard - August 2014

Millennium Development Goals: At a Glance

Supplementary appendix

Main developments in past 24 hours

Finding the missing TB cases

DM and TB Double Burden. Anil Kapur

10th International Conference on MCH handbook Maternal and Child Health Handbook born in Japan, flourishing around the world

O c t o b e r 1 0,

Call to Action To Accelerate Access to DR-TB Drugs: 2016 Update

Updates on the global TB Global TB burden Policy response Treatment approaches

TB in the SEA Region. Review Plans and Progress. Dr Md Khurshid Alam Hyder Medical Officer TB SEARO/WHO

Disparities in access: renewed focus on the underserved. Rick Johnston, WHO UNC Water and Health, Chapel Hill 13 October, 2014

511,000 (57% new cases) ~50,000 ~30,000

Global Measles and Rubella Update. April 2018

Global reductions in measles mortality and the risk of measles resurgence

POTENTIAL TECHNOLOGIES TO SOLVE COMMON HEALTH PROBLEMS IN SOUTH EAST ASIA COUNTRIES

Seeking Opportunities from Complex Regulatory Challenges for Halal Cosmetic Products in ASEAN Market

WHO Global Malaria Programme. February 2009

TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION In the WHO Western Pacific Region 2002 Report

Tuberculosis Surveillance Center-RIT/JATA TUBERCULOSIS IN JAPAN

JOINT TB AND HIV PROGRAMMING

Epidemiology and Prevention. Estimated Global, Regional, and National Disease Burdens Related to Sugar-Sweetened Beverage Consumption in 2010

Procedure for Expedited Review of imported pre-qualified vaccines for use in national immunization programmes

Impact Dashboard - October 2014

Education, Literacy & Health Outcomes Findings

Global Measles and Rubella Update November 2018

Experiences on Workforce Development in Other Regions

Potentials for Integrating CVD Surveillance and HIV Surveillance

Towards an ASEAN Community Guest Lecture

Global Measles and Rubella Update October 2018

What is Treatment Optimisation (TO)

Measuring Progress Towards the Millennium Development Goals for TB Control

EXPLANATION OF INDICATORS CHOSEN FOR THE 2017 ANNUAL SUN MOVEMENT PROGRESS REPORT

Discussion. Definition of Impact Analytic issues surrounding impact measures

Prevalence Survey -Global Overview- Background, Survey results since 2007, Lessons and Implications to the program Ikushi Onozaki MD MPH WHO HQ STB

Assessment of the performance of TB surveillance in Kenya main findings, key recommendations and associated investment plan

World Health organization/ International Society of Hypertension (WH0/ISH) risk prediction charts

TUBERCULOSIS CONTROL WHO WESTERN PACIFIC REGION

Paediatric TB: disease burden estimation and the opportunities it creates to strengthening surveillance

ANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012

Transcription:

GBD2013 Tuberculosis estimates of mortality, incidence and prevalence Theo Vos Professor of Global Health March 31, 2015

Tuberculosis estimation strategy 1) Goal: Use all available data on different outcomes and simultaneously estimate incidence, remission, excess mortality, prevalence, and cause-specific mortality 2) Data: annual case notifications, expert judgment on case detection rate, prevalence surveys, and cause of death data 3) Tools: DisMod-MR 2.0; the GBD 2013 Bayesian metaregression environment

Case-notifications: improving over time 1) Detail by age and sex and form (smear-positive, smearnegative, extra-pulmonary), varies by country. 2) Much more detailed data in recent years. Notifications in the 1990s, e.g., in India, very poor with many TB suspects included. 3) Major variation across countries in percentage E-P not explained by HIV status 4) GBD 2013 used various regression methods to complete age-sex-clinical-type matrix, dealing with o o Missingness age, sex, SN, EP Redistribution of relapse cases & smear unknown

Expert judgment on case-detection rate 1) Major gap in tuberculosis epidemiology is the true incidence rate. Very few population cohort studies with active surveillance. 2) WHO and GBD 2013 used expert judgment on the case detection rate (with subjective uncertainty intervals) as an input into the estimation process. 3) Impossible to validate expert judgment.

National TB prevalence surveys Bangladesh: 2001, 2007 Brunei Darussalam: 1986 Botswana: 1956 China: 1979, 1984, 1990, 2000, 2010 Eritrea: 2005 Ethiopia: 2011 Ghana: 1957 Gambia: 2012 Indonesia: 1980, 2004 Japan: 1953, 1958 Cambodia: 2002, 2011 Korea: 1965, 1970, 1975, 1980, 1985, 1990, 1995 Laos: 2010 Lesotho: 1956 Myanmar: 1972, 2009 Mauritius: 1972, 2009 Nigeria: 1955, 2012 Philippines: 1981, 1997, 2007 Rwanda: 2012 Saudi Arabia: 1993 Thailand: 2012 Tanzania: 2012 Vietnam: 2006

TB prevalence surveys used in GBD2013 1) Excluded pre-1985 surveys 2) Used 27 national and 24 subnational prevalence surveys in 24 countries 3) Marked surveys by case ascertainment method: o Culture + (reference) o Smear + 4) In DisMod-MR 2.0 added noise (greater non-sampling error) to subnational surveys 5) Adjusted prevalence data to account for extrapulmonary TB using same inflation factors as for incidence data 6

Tuberculosis mortality 1) Mortality models based on nationally representative vital registration and verbal autopsy data Data type Vital Registration 2,731 Verbal autopsy 166 Number of country- or site-years 2) Cause of Death Ensemble modeling (CODEm): tests wide range of models with variations in quantity of interest (logit cause fraction or log rate), model function (space-time GPR, mixed effects) and predictive covariates. 3) Create combinations ensembles of the best performing models. 4) Statistical tests of out-of-sample predictive validity all models 5) Select the best performing model or ensemble of models

Tuberculosis mortality: covariates Covariate Level Direction Alcohol per capita 2 pos Total cigarettes (5 year lag) 1 pos Average fasting plasma glucose 1 pos Average years of education 3 neg health_system_access 1 neg Lagged GDP 3 neg % underweight (<-2z) 1 pos Prevalence indoor air pollution 1 pos % Population density (500-1000/km 2 ) 2 pos % Population density (>1000/km 2 ) 2 pos 8

Tuberculosis mortality 1) ICD-10 has a code for HIV and mycobacterial infection (B30.0), but it is not used consistently; no code in ICD-9 2) Redistribute TB deaths to HIV in 52 countries by examining the relative age pattern of mortality by cause over time 3) but for non-fatal estimation we use all TB mortality as incidence and prevalence data do not distinguish by HIV-status

Relative age pattern of tuberculosis mortality in South Africa

DisMod-MR 2.0 1. As previous versions of dismod, it ensures consistency between epidemiological estimates for a particular disease or sequela of a disease 2. In order to evaluate all available info on a disease that passes inclusion criteria we use meta-regression to crosswalk data to reference values of critical characteristics such as case definition, case ascertainment method, representativeness 3. All countries are evaluated in a Bayesian framework implemented as a cascade from global to 7 superregions to 21 regions, 188 countries and subnational units for selected countries (China, Mexico and UK in GBD2013)

DisMod-MR 2.0 Inputs: 1) Adjusted WHO tuberculosis case notifications 2) Prevalence surveys 3) Tuberculosis mortality estimates 4) Remission estimates 5) Excess mortality estimates Outputs: Internally consistent estimates of incidence, remission, excess mortality, prevalence, and cause-specific mortality for 188 countries for 1990, 1995, 2000, 2005, 2010, and 2013

DisMod-MR 2.0 1) Incidence, remission and excess mortality are the primary hazards 2) Prevalence is a derived quantity 3) Cause-specific mortality rate (CSMR) from CODEm is equivalent to excess mortality rate / prevalence 4) That means that dismod is underspecified when we feed in incidence, prevalence and CSMR only 5) we made pre-dismod estimates of remission and excess mortality to guide the calculations

Excess mortality rates 1) Excess mortality from case notification data and TB deaths from 70 countries (743 country year observations) where incidence and death notifications are believed to be (near) complete; 1980 onwards for most countries but supplemented with 1950-1980 data from AUS, GBR, DLD, CAN, USA & JAP 2) Regression of logit ratio incidence to mortality, lagged GDP and country random effects

Remission 1) Remission from incidence to prevalence ratios for country/year combinations for which we had prevalence surveys: simple regression with dummies for age and sex and random effects on geography p = i av dur and remission + exc mort = 1 av dur

Tuberculosis: simultaneous estimation of incidence, prevalence, and death

Estimating HIV-free TB morbidity Tuberculosis all forms incidence and prevalence estimates generated by DisMod- MR 2.0 Reviewed the literature and used meta-regression to estimate RR of TB incidence in HIV+ individuals in the absence of ARTs Since RR is a function of CD4 count and ART parsed out the ratios using additional studies ART Status CD4 count RR On ART All 1.7 (1.2 2.3) No ART All 8.7 (5.9 11.7) <200 15.7 (10.6 21.1) 200-350 10.8 (7.3 14.5) >350 3.2 (2.2 4.3) Computed population attributable fractions (PAF) for each category using estimates of HIV prevalence for each category; aggregated these to get a single PAF

Global tuberculosis deaths: 1990-2013

Global tuberculosis deaths in 2013: more in men than women

Age-standardized TB incidence (no HIV): 2013

Age-standardized TB mortality (no HIV): 2013

Global annualized percent change Tuberculosis, all forms Parameter 1990-2000 2000-2013 Incidence 0.55 (0.36 to 0.72) -0.67 (-0.78 to -0.58) Prevalence 0.83 (0.70 to 0.98) -1.35 (-1.44 to -1.25) Mortality -2.85 (-3.59 to -2.20) -3.66 (-4.32 to -2.99) Tuberculosis, no TB-HIV Parameter 1990-2000 2000-2013 Incidence 0.03 (-0.18 to 0.24) -0.59 (-0.71 to -0.48) Prevalence 0.40 (0.22 to 0.58) -1.28 (-1.39 to -1.17) Mortality -3.30 (-4.08 to -2.59) -3.66 (-4.36 to -2.94)

Understanding age-specific relationships incidence, prevalence, and mortality 1) Bayesian meta-regression points to the markedly different relationship between incidence, prevalence, and death with age. More direct studies on this would help narrow the range of plausible relationships. 2) Prevalence surveys with linkage to incidence registries with identifiers could allow more direct quantification of duration.

Tuberculosis in India 1) Large share of cases and deaths in 2013 are in India. 2) Huge uncertainty in the epidemiology of tuberculosis, particularly at younger ages in India. 3) More locality-specific verbal autopsy, registration, and prevalence data will be essential to resolving global epidemiological questions.

Spatial analysis of tuberculosis 1) As with other diseases, e.g., malaria, spatially detailed analysis of tuberculosis may help narrow the uncertainty in the TB incidence, prevalence, and death estimates. 2) Tuberculosis likely spatially heterogeneous, substantial data from notifications combined with prevalence surveys could be analyzed.